Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Breast09 first-line HER2-positive metastatic breast cancer study
CTR20212454Phase 3Active
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab deruxtecan, pertuzumab, trastuzumab in breast cancer, sponsored by Daiichi Sankyo Co., Ltd.. Started Dec 2021; status: active.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20212454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212454.